GLP-1 receptor agonists represent one of the most actively researched classes of peptide-based compounds in contemporary metabolic science. These synthetic analogues of the naturally occurring incretin hormone glucagon-like peptide-1 have been the subject of extensive clinical investigation over the past two decades. This guide provides an overview of the major GLP-1 receptor agonists, their mechanisms, and the research landscape - with particular attention to the Australian context.
Understanding GLP-1 Biology
Glucagon-like peptide-1 is secreted by L-cells in the distal intestine in response to nutrient ingestion. Its physiological roles include:
- Glucose-dependent insulin secretion from pancreatic beta cells
- Suppression of glucagon release from alpha cells
- Delayed gastric emptying, contributing to postprandial glucose regulation
- Central appetite modulation via hypothalamic and brainstem receptors
The native peptide has a half-life of approximately two minutes due to rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). This pharmacokinetic limitation has driven the development of structurally modified analogues with extended half-lives and enhanced receptor activity.
Semaglutide
Semaglutide is a modified GLP-1 receptor agonist featuring an Aib substitution at position 8 (conferring DPP-4 resistance) and a C-18 fatty acid acyl chain that enables albumin binding. These modifications produce a half-life of approximately one week, allowing once-weekly subcutaneous or once-daily oral administration.
Clinical Trial Data
The SUSTAIN programme (Semaglutide Unabated Sustainability Study in Treatment of Type 2 Diabetes) comprised multiple Phase 3 randomised controlled trials. Key findings include:
- SUSTAIN 1-6: Researchers observed dose-dependent reductions in HbA1c and body weight across diverse populations with type 2 diabetes
- SUSTAIN-6: A cardiovascular outcomes trial that reported a statistically significant reduction in major adverse cardiovascular events (MACE) - the first CV outcomes data for semaglutide
- SUSTAIN-J programme: Trials conducted in Japanese and East Asian populations
The PIONEER programme evaluated oral semaglutide, demonstrating that GLP-1 RA activity could be achieved through oral administration using the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate).
The SELECT trial (2023) examined semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, reporting reductions in MACE - a finding that extended the research interest in GLP-1 RAs beyond glycaemic endpoints.
Mechanism Summary
Semaglutide acts as a full agonist at the GLP-1 receptor, activating adenylyl cyclase and increasing intracellular cAMP. Its prolonged receptor engagement distinguishes it from shorter-acting GLP-1 RAs.
Tirzepatide
Tirzepatide represents a novel pharmacological approach as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It was designed with a C20 fatty diacid moiety for albumin binding, conferring a half-life of approximately five days.
Clinical Trial Data
- SURPASS programme: Phase 3 trials in type 2 diabetes. Researchers observed that tirzepatide produced greater HbA1c reductions than semaglutide 1 mg in head-to-head comparisons (SURPASS-2)
- SURMOUNT programme: Trials examining tirzepatide in obesity. SURMOUNT-1 reported mean body weight reductions of up to 20.9% at the highest dose (15 mg) over 72 weeks
- SURMOUNT-MMO: A mechanistic study examining metabolic effects beyond glycaemic control
Dual Agonism Rationale
Researchers have hypothesised that combined GIP and GLP-1 receptor activation may produce additive or synergistic effects on insulin secretion, glucagon regulation, and energy expenditure. The relative contribution of each receptor to tirzepatide’s observed effects remains an active area of investigation.
Liraglutide
Liraglutide was among the first long-acting GLP-1 receptor agonists, featuring a C-16 fatty acid chain that enables albumin binding and confers a half-life of approximately 13 hours. It requires once-daily subcutaneous injection.
Clinical Trial Data
The LEAD programme (Liraglutide Effect and Action in Diabetes) comprised six Phase 3 trials:
- LEAD 1-6: Researchers observed consistent HbA1c reductions and modest weight loss across the programme
- LEAD-6: Compared liraglutide to exenatide twice daily, reporting superior glycaemic control with liraglutide
- SCALE trial: Examined liraglutide 3.0 mg in a weight management context
Liraglutide was the subject of the LEADER trial, a cardiovascular outcomes study that reported a reduction in MACE, contributing to the evidence base for cardiovascular effects of GLP-1 RAs.
Exenatide
Exenatide is based on exendin-4, a GLP-1 receptor agonist originally isolated from the saliva of the Gila monster (Heloderma suspectum). It was the first GLP-1 RA approved for clinical use and is available in twice-daily and once-weekly (exenatide extended-release) formulations.
Key Research
- Exendin-4 shares approximately 53% sequence homology with native GLP-1 but is resistant to DPP-4 degradation
- The DURATION programme evaluated once-weekly exenatide extended-release
- EXSCEL (Exenatide Study of Cardiovascular Event Lowering) was a large cardiovascular outcomes trial
Australian Research Context
Several GLP-1 receptor agonists are approved by the Therapeutic Goods Administration (TGA) for specific therapeutic indications in Australia. They are generally classified as Schedule 4 (Prescription Only) medicines under the Poisons Standard.
Australian researchers have contributed to the global GLP-1 RA evidence base. ClinicalTrials.gov lists multiple trials conducted at Australian sites, including substudies examining cardiovascular, renal, and hepatic outcomes in Australian populations.
The TGA has approved semaglutide (subcutaneous and oral formulations), tirzepatide, liraglutide, and exenatide for specific indications. Approval status and approved indications are updated periodically and should be verified against the Australian Register of Therapeutic Goods (ARTG).
Related Compounds
Beyond the major GLP-1 RAs discussed above, several related compounds are generating research interest:
- Retatrutide - A triple agonist targeting GLP-1, GIP, and glucagon receptors
- BPC-157 - A pentadecapeptide with diverse preclinical research findings
- TB-500 - Thymosin beta-4 fragment with tissue repair research
- CJC-1295/Ipamorelin - Growth hormone secretagogue combination
For a broader overview of research methodology, see our Research page.
For research literacy and educational purposes only. This content does not constitute medical advice or therapeutic recommendation. Consult a qualified healthcare professional for medical decisions.